A fibric acid derivative, reduces total plasma triglycerides by the activation of peroxisome proliferator-activated receptor-α (PPAR-α) and lipoprotein lipase, thereby leading to a reduced production of apoprotein CIII, and an increased synthesis of apoproteins AI and AII, and fatty acid transport protein. Thus, resulting to an increased VLDL catabolism, fatty acid oxidation, and elimination of atherogenic triglyceride-rich particles; as a result of a decrease in VLDL and LDL and an increase in HDL levels.